



*Sequence 131*

PS Claim 1; Fig 1A-B; 67pp; English.

XX The present sequence represents a human progesterone receptor complex

CC p23-like protein (PR23p). PR23p is used to treat neurological

CC disorders. Antagonists of PR23p are useful for treating reproductive,

CC immunological or neoplastic disorders. Probes and primers based on the

CC PR23p polynucleotides can be used for diagnosis, detection and screening

CC of homologues, and amplification of PR23p genes. Antisense PR23p

CC polynucleotides can be used to decrease or inhibit expression of PR23p.

XX

Sequence 156 AA:

Query Match 100.0%; Score 849; DB 20; Length 156;

Best Local Similarity 100.0%; Pred. No. 1e-82;

Matches 156; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MARQHARTLWYDRPMYVMEFCVEDSDVHVLIEDHRIYFSCKNADGYELNIEIFYAKV 60

DB 1 MARQHARTLWYDRPMYVMEFCVEDSDVHVLIEDHRIYFSCKNADGYELNIEIFYAKV 60

QY 61 NSKSDQKRSRSTICFVRKKEKAYAMPRLTKEDIKPWLSDVDPMWRWEGDEEMELAH 120

DB 61 NSKSDQKRSRSTICFVRKKEKAYAMPRLTKEDIKPWLSDVDPMWRWEGDEEMELAH 120

QY 121 VEHYAEILKKVSTKRPPAMDLDSDSADATS 156

DB 121 VEHYAEILKKVSTKRPPAMDLDSDSADATS 156

RESULT 2

AAAM39556 standard; Protein; 156 AA.

XX

AAAM39556;

XX

22-OCT-2001 (first entry)

XX

Human polypeptide SEQ ID NO 2701.

XX

Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;

KW peripheral nervous system; neuropathy; central nervous system; CNS;

KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;

KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;

KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;

XX

leukemia.

XX

Homo sapiens.

OS

XX

WO200153312-A1.

PN

XX

26-JUL-2001.

PD

XX

26-DEC-2000; 2000WO-US34263.

PF

XX

21-JAN-2000; 2000US-0488725.

PR

XX

25-APR-2000; 2000US-0552317.

PR

XX

09-JUL-2000; 2000US-0598042.

PR

XX

19-JUL-2000; 2000US-0620312.

PR

XX

03-AUG-2000; 2000US-0653450.

PR

XX

14-SEP-2000; 2000US-0662191.

PR

XX

19-OCT-2000; 2000US-0693036.

PR

XX

29-NOV-2000; 2000US-0727344.

PR

XX

(HYSE-) HYSEQ INC.

PA

XX

Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;

PI Wang J, Wang Z, Wehman T, Xu C, Xue AJ, Yang Y, Zhang J;

PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;

XX

WPI; 2001-442253/47.

DR

XX

N-PSDB; AA158712.

DR

XX

Novel nucleic acids and polypeptides, useful for treating disorders

PT

PT such as central nervous system injuries -

XX

XX Example 4; SEQ ID NO 2701; 10078pp; English.

PS

XX The invention relates to human nucleic acids (AA157798-AA161369) and

CC the encoded polypeptides (AA38642-AA42213) with nootropic,

CC immunosuppressant and cytostatic activity. The polynucleotides are useful

CC in gene therapy. A composition containing a polypeptide or polynucleotide

CC of the invention may be used to treat diseases of the peripheral nervous

CC system, such as peripheral nervous injuries, peripheral neuropathy and

CC localized neuropathies and central nervous system diseases, such as

CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic

CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the

CC utilisation of the activities such as: Immune system suppression,

CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic

CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,

CC assays for receptor activity, arthritis and inflammation, leukemias and

CC C.N.S disorders.

CC Note: The sequence data for this patent did not form part of the prior

CC specification.

XX

Sequence 156 AA:

QY 1 MARQHARTLWYDRPMYVMEFCVEDSDVHVLIEDHRIYFSCKNADGYELNIEIFYAKV 60

DB 1 MARQHARTLWYDRPMYVMEFCVEDSDVHVLIEDHRIYFSCKNADGYELNIEIFYAKV 60

QY 61 NSKSDQKRSRSTICFVRKKEKAYAMPRLTKEDIKPWLSDVDPMWRWEGDEEMELAH 120

DB 61 NSKSDQKRSRSTICFVRKKEKAYAMPRLTKEDIKPWLSDVDPMWRWEGDEEMELAH 120

QY 121 VEHYAEILKKVSTKRPPAMDLDSDSADATS 156

DB 121 VEHYAEILKKVSTKRPPAMDLDSDSADATS 156

RESULT 3

AAAM39657 standard; Protein; 543 AA.

XX

AAAM39657;

XX

22-OCT-2001 (first entry)

XX

Human polypeptide SEQ ID NO 2802.

DE

XX

Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;

KW peripheral nervous system; neuropathy; central nervous system; CNS;

KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;

KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;

KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;

KW leukemia.

XX

Homo sapiens.

OS

XX

WO200153312-A1.

PN

XX

26-JUL-2001.

PD

XX

26-DEC-2000; 2000WO-US34263.

PF

XX

21-JAN-2000; 2000US-0488725.

PR

XX

25-APR-2000; 2000US-0552317.

PR

XX

09-JUL-2000; 2000US-0598042.

PR

XX

19-JUL-2000; 2000US-0620312.

PR

XX

03-AUG-2000; 2000US-0653450.

PR

XX

14-SEP-2000; 2000US-0662191.

PR

XX

19-OCT-2000; 2000US-0693036.

PR

XX

29-NOV-2000; 2000US-0727344.

PR